Table 1 Patient demographic, tumor, and treatment characteristics by initial endocrine therapy status.
Variable | Total (n = 202) | SERM (n = 140) | AI (n = 62) | p-value |
|---|---|---|---|---|
Demographic & clinicopathologic characteristics | ||||
Age at diagnosis | ||||
Median age (IQR) | 47.6 (6.0) | 47.9 (5.9) | 46.5 (6.0) | p = 0.64 |
Histology subtype, n(%) | ||||
ILC | 186 (92.1) | 126 (90.0) | 60 (96.7) | p = 0.100 |
Mixed ILC/IDC | 16 (7.9) | 14 (10.0) | 2 (3.2) | |
Pleomorphic features, n(%) | ||||
Yes | 19 (9.4) | 13 (9.3) | 6 (9.7) | p = 0.930 |
Lymphovascular invasion, n(%) | ||||
Yes | 12 (6.1) | 10 (7.5) | 2 (3.2) | p = 0.250 |
Tumor receptor status, n(%) | ||||
ER + PR + HER2- | 180 (89.1) | 126 (90.0) | 54 (87.1) | p = 0.409 |
ER + PR- HER2- | 9 (4.5) | 7 (5.0) | 2 (3.2) | |
ER + PR + HER2+ | 12 (5.9) | 6 (4.3) | 6 (9.7) | |
ER- PR + HER2- | 1 (0.5) | 1 (0.7) | 0 | |
Grade, n(%) | ||||
1 | 51 (26.3) | 35 (26.1) | 16 (26.7) | p = 0.545 |
2 | 133 (68.6) | 92 (68.7) | 41 (68.3) | |
3 | 10 (5.2) | 7 (5.2) | 3 (5.0) | |
T category, n(%) | ||||
pT1 | 86 (42.8) | 67 (48.2) | 19 (30.7) | p < 0.001 |
pT2 | 63 (31.3) | 48 (34.5) | 15 (24.2) | |
pT3 | 52 (25.9) | 24 (17.3) | 28 (45.2) | |
N category, n(%) | ||||
pN0 | 124 (61.4) | 94 (67.1) | 30 (48.4) | p = 0.051 |
pN1 | 52 (25.7) | 31 (22.1) | 21 (33.9) | |
pN2 | 15 (7.4) | 10 (7.1) | 5 (8.1) | |
pN3 | 11 (5.5) | 5 (3.6) | 6 (9.7) | |
Overall stage, n(%) | ||||
I | 63 (31.2) | 53 (37.9) | 10 (16.1) | p = 0.003 |
II | 100 (49.5) | 66 (47.1) | 34 (54.8) | |
III | 39 (19.3) | 21 (15.0) | 18 (29.0) | |
Treatment characteristics | ||||
Surgical therapy, n(%) | ||||
Lumpectomy + radiation | 69 (34.2) | 55 (39.3) | 14 (22.6) | p = 0.003 |
Lumpectomy | 6 (3.0) | 2 (1.4) | 4 (6.5) | |
Mastectomy | 76 (37.6) | 56 (40.0) | 20 (32.3) | |
Mastectomy + radiation | 51 (25.3) | 27 (19.3) | 24 (38.7) | |
Chemotherapy, n(%) | ||||
Neoadjuvant chemotherapy | 34 (16.8) | 21 (15.0) | 13 (21.0) | p = 0.296 |
Adjuvant chemotherapy | 75 (37.1) | 48 (34.3) | 27 (43.6) | p = 0.209 |
Switched endocrine therapy (SERM & AI) | ||||
Yes | 48 (23.8) | 45 (32.1) | 3 (4.8) | p < 0.001 |
Adjuvant ovarian suppression, n(%) | ||||
Yes | 66 (32.7) | 17 (12.1) | 49 (79.0) | p < 0.001 |
